CTI BioPharma (FRA:CEPS) Debt-to-Revenue : 0.51 (As of Mar. 2023)

CTI BioPharma Debt-to-Revenue Chart

CTI BioPharma Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
Debt-to-Revenue		Get a 7-Day Free Trial					0.54	3.67	N/A	N/A	0.93

CTI BioPharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Revenue	Get a 7-Day Free Trial															5.27	1.00	0.68	0.59	0.51

Competitive Comparison of CTI BioPharma's Debt-to-Revenue

For the Biotechnology subindustry, CTI BioPharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CTI BioPharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's Debt-to-Revenue falls into.

CTI BioPharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

CTI BioPharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

CTI BioPharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2023) Revenue data.

CTI BioPharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CTI BioPharma (FRA:CEPS) Business Description